Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis

Journal of Infectious Diseases

Volumn 202, Issue 8, 2010, Pages 1265-1272

  Lahey, Timothy ^a   Sheth, Siddharth ^a   Matee, Mecky ^d   Arbeit, Robert ^b   Horsburgh, C Robert ^c   Mtei, Lillian ^d   MacKenzie, Todd ^a   Bakari, Muhammad ^d   Vuola, Jenni M ^e,f   Pallangyo, Kisali ^d   Von Reyn, C Fordham ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f GLAXOSMITHKLINE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIGEN 85; BCG VACCINE; CD4 ANTIGEN; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; PLACEBO; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN;

ADULT; ARTICLE; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CELL LYSATE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TANZANIA; TUBERCULOSIS; BLOOD; IMMUNOLOGY; RISK FACTOR;

ADULT; ANTIGENS, BACTERIAL; BCG VACCINE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TANZANIA; TUBERCULOSIS;

EID: 77957009510     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656332     Document Type: Article

References (48)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938-940.
2. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164-175.
3. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-1961. (Pubitemid 127634266)
4. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367-373.
5. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177:1164-1170. (Pubitemid 351717577)
6. Pai M, Zwerling A, Menzies D, Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-184.
7. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64. (Pubitemid 38997752)
8. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149:777-787.
9. Silveira H, Ordway D, Dockrell H, Jackson M, Ventura F. Cell-mediated immune responses to mycobacterial antigens in patients with pulmonary tuberculosis and HIV infection. Clin Exp Immunol 1997; 110:26-34. (Pubitemid 27428511)
10. Oh MD, Kang CI, Kim US, et al. Cytokine responses induced by Mycobacterium tuberculosis in patients with HIV-1 infection and tuberculosis. Int J Infect Dis 2005; 9:110-116.
11. Rangaka MX, Diwakar L, Seldon R, et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007; 44:1639-1646. (Pubitemid 46871513)
12. Vuola JM, Ristola MA, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003; 17:2351-2355. (Pubitemid 38147021)
13. Waddell RD, Chintu C, Lein AD, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000; 30(suppl 3):S309-S315.
14. Vuola JM, Ristola MA, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003; 17:2351-2355. (Pubitemid 38147021)
15. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12:1037-1041.
16. Matee M, Lahey T, Vuola JM, et al. Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis 2007; 195:118-123. (Pubitemid 44958233)
17. Waddell RD, von Reyn CF, Baboo KS, Mwinga A, Chintu C, Zumla A. The effects of BCG immunization and human immunodeficiency virus infection on dual skin test reactions to purified protein derivative and Mycobacterium avium sensitin among adults in Zambia. Int J Tuberc Lung Dis 1999; 3:255-260.
18. von Reyn CF, Barber TW, Arbeit RD, et al. Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellulare complex among healthy subjects: an international study of dominant mycobacterial skin test reactions. J Infect Dis 1993; 168:1553-1558.
19. von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5:1122-1128.
20. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis 1996; 174:113-119.
21. Ravn P, Boesen H, Pedersen BK. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 1997; 158:1949-1955.
22. Lowry PW, Ludwig TS, Adams JA, et al. Cellular immune responses to four doses of percutaneous bacille Calmette-Guérin in healthy adults. J Infect Dis 1998; 178:138-146.
23. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol 1999; 163:2249-2255.
24. Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180:3569-3577.
25. Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359:1393-1401. (Pubitemid 34442380)
26. Flahiff EW. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions. Am J Hyg 1939; 30:69-74.
27. Ziegler JE, Edwards ML, Smith DW. Exogenous reinfection in experimental airborne tuberculosis. Tubercle 1985; 66:121-128.
28. Edwards LB, Palmer CE. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci 1968; 154:140-148.
29. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-1345.
30. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29-35.
31. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698-702.
32. Glynn JR, Crampin AC, Yates MD, et al. The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi. J Infect Dis 2005; 192:480-487.
33. Lockman S, Sheppard JD, Braden CR, et al. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients. J Clin Microbiol 2001; 39:1042-1047.
34. Shamputa IC, Van Deun A, Salim MA, et al. Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection. Trop Med Int Health 2007; 12:700-708.
35. Whalen CC, Johnson JL, Okwera A, et al; Uganda-Case Western Reserve University Research Collaboration. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-808.
36. von Reyn CF, Horsburgh CR. Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 173:133-134.
37. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48:954-962.
38. Lahey T, Matee M, Mtei L, et al. Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis 2009; 9:21.
39. Winkler S, Necek M, Winkler H, et al. Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from central Africa. Microbes Infect 2005; 7:1161-1169. (Pubitemid 41316689)
40. Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20:821-829. (Pubitemid 43731563)
41. Day CL, Mkhwanazi N, Reddy S, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008; 197:990-999.
42. Elliott AM, Hurst TJ, Balyeku MN, et al. The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study. Int J Tuberc Lung Dis 1999; 3:239-247.
43. Dheda K, Udwadia ZF, Huggett JF, Johnson MA and Rook GAW. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005; 11:195-202. (Pubitemid 40577168)
44. Lawn S, Bangani N, Vogt M, et al. Utility of interferon-gamma ELI-SPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis 2007; 7:99. (Pubitemid 47617279)
45. Lalvani A. Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? Clin Infect Dis 2004; 38:757-759.
46. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38:754-756. (Pubitemid 38333874)
47. Wilkinson KA, Seldon R, Meintjes G, et al. Dissection of regenerating T cell responses against tuberculosis in HIV infected adults with latent tuberculosis. Am J Respir Crit Care Med 2009; 180:674-683.
48. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500-1507. (Pubitemid 40628639)